Signal Activated RNAi Construct for Specific Disease Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
RNA interference (RNAi) therapies face challenges such as insufficient disease repression, non-specific harm to healthy cells, drug resistance in cancer cells, temporary inhibition of viral replication, and off-target effects due to recognition by cellular immunity.
Innovation Solution
A signal-activated polynucleotide construct comprising a guide sequence and a sense sequence capable of forming a duplex region that can be cleaved by Dicer to generate siRNA or miRNA, with a signal detecting sequence that inhibits or allows the generation of siRNA or miRNA based on the presence of signal polynucleotides, minimizing off-target effects and immune recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi is used to repress disease-associated mRNAs, then therapeutic efficacy is improved, but off-target effects and immune activation increase
Solution Approach 1:
The patent applies dynamics by creating a switchable RNAi system that transitions between inactive and active states based on cellular signals. The RNAi construct is designed to be activated only when specific signaling molecules are present, allowing the system to adapt its state according to disease conditions while avoiding constitutive activation that would cause off-target effects and immune activation.
Solution Approach 2:
The patent uses signaling molecules as intermediaries to control RNAi activation. These signaling molecules act as mediators that bridge the gap between disease state detection and RNAi activation, ensuring that therapeutic action is triggered only when truly needed, thereby reducing off-target effects and immune activation.
2Reliability
If high potency RNAi is delivered to cancer cells, then disease repression is improved, but non-specific harm to healthy cells increases
Solution Approach 1:
The patent applies local quality by creating spatial and temporal specificity in RNAi activation. The system is designed to activate RNAi only in specific cellular contexts where disease signals are present, rather than providing uniform high-potency RNAi throughout. This localized activation maintains strong disease repression while minimizing harm to healthy cells that lack the activating signals.
3Reliability
If RNAi is used to inhibit viral replication, then viral suppression is improved, but viral reemergence occurs after treatment stops
Solution Approach 1:
The patent applies feedback by designing an RNAi system that responds to viral presence through signaling molecules. When viral replication occurs, signaling molecules are activated which in turn trigger RNAi activation. This feedback loop ensures that RNAi continues to suppress viral replication as long as viral signals are present, providing sustained suppression rather than temporary inhibition.
4Device complexity
If conventional RNAi constructs are used, then simplicity is maintained, but specificity and reduced side effects are insufficient
Solution Approach 1:
The patent applies segmentation by dividing the RNAi construct into distinct functional modules: the RNAi-triggering sequence, the guide sequence, and the sense sequence. This modular design maintains relative simplicity while enabling precise control over activation through the integrated signaling response elements, thereby improving specificity without excessive complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances specificity and reduces side effects by activating RNAi only in the presence of disease-associated signals, minimizing harm to healthy cells and maintaining therapeutic efficacy while avoiding immune activation.
Implementation Method 1
a signal detecting sequence capable of hybridizing with either: (a) one or more signal polynucleotides, or, (b) one or more regions comprising part of the guide sequence and/or part of the sense sequence
Implementation Method 2
a guide sequence and a sense sequence capable of forming a duplex region that can either become or be cleaved by Dicer to generate an siRNA or an miRNA
Data Source
AI summary
The invention provides compositions and methods for signal activated RNA interference (saRNAi), preferably in vivo. The invention provides polynucleotides that switches between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a substrate that can be processed by proteins of the RNAi pathway (such as Dicer). The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network. In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides.